GeNeuro Announces Positive 6-Month Phase IIa Data for GNbAC1 in Adults with Type 1 Diabetes
Geneva, Switzerland, 26 September 2018 – 7:30am CEST – GeNeuro (Euronext Paris: CH0308403085 - GNRO), a biopharmaceutical company developing new treatments for neurological and autoimmune diseases, announced that its Pha ...